Cho et al. revealed that in non-small-cell lung cancer, reduced levels of TNFRSF9 expression in Tregs improve OS and responses to anti-PD-1 antibody immunotherapy. This evidence concerns the gene TNFRSF9 and non-small cell lung carcinoma.